JPMorgan Chase & Co. Increases Clorox (NYSE:CLX) Price Target to $173.00

Clorox (NYSE:CLX) had its price objective increased by JPMorgan Chase & Co. from $171.00 to $173.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 18.51% from the stock’s previous close.

Several other research firms have also recently commented on CLX. Barclays lowered their target price on Clorox from $139.00 to $130.00 and set an “underweight” rating on the stock in a research report on Friday, January 17th. DA Davidson upped their price objective on shares of Clorox from $153.00 to $171.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Evercore ISI lowered their target price on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research note on Monday, October 14th. TD Cowen upgraded shares of Clorox from a “sell” rating to a “hold” rating and raised their price objective for the company from $155.00 to $170.00 in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company upped their target price on Clorox from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $158.21.

Clorox Stock Down 1.5 %

NYSE:CLX opened at $145.98 on Tuesday. The firm has a market capitalization of $18.07 billion, a PE ratio of 50.86, a price-to-earnings-growth ratio of 2.92 and a beta of 0.42. Clorox has a 52 week low of $127.60 and a 52 week high of $171.37. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08. The stock has a 50 day moving average of $162.25 and a 200-day moving average of $158.76.

Clorox (NYSE:CLX) last announced its quarterly earnings results on Monday, February 3rd. The company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.16. Clorox had a net margin of 4.78% and a return on equity of 316.08%. During the same quarter in the prior year, the business earned $2.16 earnings per share. Analysts predict that Clorox will post 6.86 EPS for the current year.

Institutional Trading of Clorox

Hedge funds and other institutional investors have recently modified their holdings of the business. Brooklyn Investment Group boosted its position in Clorox by 163.8% during the 4th quarter. Brooklyn Investment Group now owns 153 shares of the company’s stock worth $25,000 after acquiring an additional 95 shares during the period. Prospera Private Wealth LLC acquired a new stake in shares of Clorox during the third quarter worth approximately $27,000. Continuum Advisory LLC grew its position in Clorox by 300.0% during the third quarter. Continuum Advisory LLC now owns 184 shares of the company’s stock valued at $30,000 after purchasing an additional 138 shares in the last quarter. Asset Planning Inc acquired a new position in Clorox in the 4th quarter valued at approximately $32,000. Finally, Halbert Hargrove Global Advisors LLC acquired a new stake in shares of Clorox during the 4th quarter valued at $36,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.